Innostellar Biotherapeutics
Latest round
- Series B
Last raised
- Jun 2024
Total raised
- Undisclosed
Investors
- 2
About Innostellar Biotherapeutics
Based in Shanghai, China, and founded in 2020, Innostellar Biotherapeutics is a biotechnology developer, dedicated to the development and manufacture of innovative drugs for gene therapy. The company has set up a branch office in Suzhou. The founder as well as the CEO, Fenghua Wang, is a director of Shanghai Ophthalmic Engineering and Technology Research Centre. It has received 3 INDs (Investigational New Drug). Innostellar Biotherapeutics has built a platform process for manufacturing AAV products in compliance with GMP regulations. The company has developed three manufacturing pipelines, LX101 for the treatment of RPE65 mutation-associated inherited retinal dystrophy (IRD), LX102 for the treatment of wet age-related macular degeneration, and LX103 for the treatment of X-linked retinal schwannoma. The company generates revenue by developing and delivering innovative medicines for the treatment of hereditary and chronic diseases of the eye. The company will accelerate the R&D and industrialisation process in the field of innovative gene therapy drugs.
Who invested in Innostellar Biotherapeutics
2 investors across 1 round
See all investors in Innostellar Biotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jun 11, 2024
Amount
Undisclosed
Investors
Questions about Innostellar Biotherapeutics
Who invested in Innostellar Biotherapeutics?
Innostellar Biotherapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Innostellar Biotherapeutics raised?
Innostellar Biotherapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Innostellar Biotherapeutics last raise money?
Innostellar Biotherapeutics's most recent round on record is a Series B, in Jun 2024.
What does Innostellar Biotherapeutics do?
Based in Shanghai, China, and founded in 2020, Innostellar Biotherapeutics is a biotechnology developer, dedicated to the development and manufacture of innovative drugs for gene therapy.
Where is Innostellar Biotherapeutics headquartered?
Innostellar Biotherapeutics is headquartered in Shanghai, China.
Which VCs invest in companies like Innostellar Biotherapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Innostellar Biotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Innostellar Biotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.